Oxford Covid-19 vaccine trial after questions were raised over its UK research. It comes after the US reported the vaccine's best dosage only worked well on younger people.
Oxford University's partner, pharmaceutical firm AstraZeneca, has announced the further trial. Earlier this week, representatives announced that clinical trials were up to 90% effective.
Although in June, Mirror had revealed a blunder – the group of trial participants who achieved this success rate had actually been given an initial half dose.
The trial continued and the main group who were given two full doses only recorded an effectiveness rate of 62%.It has now emerged the smaller group of less than 3,000 out of 24,000 trial participants on the half-dose-full-dose.
Read more on dailystar.co.uk